Volasertib preclinical activity in high-risk hepatoblastoma John Verducci2023-06-15T18:20:49+00:00November 5, 2019|Publication| Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. Read the full publication on PubMed. Share this story on social media. FacebookXLinkedInEmail
